Ph+ clinical protocols have the main focus on multiagent chemotherapy in combination with tyrosine kinase inhibitors; this combination significantly improved outcomes in adults with newly diagnosed BCR/ABL1-positive ALL [27]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.